FDA Authorizes First Eyeglass Lenses To Slow Progression Of Pediatric Myopia

The U.S. Food and Drug Administration has authorized marketing of the Essilor Stellest eyeglass lenses to correct myopia, commonly referred to as nearsightedness, with or without astigmatism and to slow the progression of the disease in children 6 to 12 years old at the initiation of treatment.

"Today's authorization brings to market a treatment option that may meaningfully reduce the likelihood of severe eyesight issues later in adult life, while also being easier to use and lower risk than the currently authorized devices that slow the progression of myopia in children," said Center for Devices and Radiological Health Director Michelle Tarver.

by Joji Xavier

For comments and feedback: contact editorial@rttnews.com